Written question asked by Lord Hunt of Kings Heath (Labour) on Wednesday, 20 July 2016, in the House of Lords. It was due for an answer on Wednesday, 3 August 2016. It was answered by Lord Prior of Brampton (Conservative) on Tuesday, 2 August 2016 on behalf of the Department of Health.

Vaccination

Question: To ask Her Majesty’s Government what assessment they have made of how best to evaluate the impact of vaccination programmes to prevent rare diseases of high severity, and in particular the cost-effectiveness of the vaccination of children.

Answer

The Government bases its evaluation of vaccination programmes on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), other expert groups and evidence from a wide range of epidemiologists and other experts. Their considerations include the impact of rare diseases, immunisation, and impacts on children. The methodology used to assess cost-effectiveness of regular (i.e. non-emergency) immunisation programmes is based on published National Institute for Health and Care Excellence guidance Guide to the methods of technology appraisal 2013. A copy of the guidance is attached.

The Cost Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP) working group has reviewed whether any changes to the methodology might be appropriate for immunisation and the Government is considering the advice.

Secondary information

Type: Written question
Reference: HL1358
Session: 2016-17
Attachment: Guide to the methods of technology appraisal 2013
Subjects: Children Cost effectiveness Vaccination Rare diseases
Link: View this Written question on www.parliament.uk

Vaccination

Secondary information

Librarians' tools